GAUZ vs KALA vs OCUL vs VUZI

For growth investors, Vuzix Corporation (VUZI) is the stronger pick with 1090% revenue growth year-over-year, versus -18.

7% for Ocular Therapeutix, Inc. (OCUL). Analysts rate KALA BIO, Inc. (KALA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ocular Therapeutix, Inc.

(OCUL) delivered a total return of -36. 3%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: OCUL returned -10. 9% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ocular Therapeutix, Inc.

(OCUL) is the lower-risk stock at 1. 11β versus Vuzix Corporation's 3. 49β — meaning VUZI is approximately 213% more volatile than OCUL relative to the S&P 500. On balance sheet safety, Vuzix Corporation (VUZI) carries a lower debt/equity ratio of 4% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vuzix Corporation (VUZI) is pulling ahead at 1090% versus -18.

7% for Ocular Therapeutix, Inc. (OCUL). On earnings-per-share growth, the picture is similar: Vuzix Corporation grew EPS 61. 1% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Over a 3-year CAGR, VUZI leads at 709. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gauzy Ltd.

Ordinary Shares (GAUZ) is the more profitable company, earning -51. 4% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps -51. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GAUZ leads at -29. 7% versus -150. 6% for KALA. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, VUZI (9.

3% yield) pays a dividend. GAUZ, KALA, OCUL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ocular Therapeutix, Inc.

(OCUL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). KALA BIO, Inc. (KALA) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OCUL: -10. 9%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GAUZ (Technology) and KALA (Healthcare) and OCUL (Healthcare) and VUZI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GAUZ is a small-cap high-growth stock; KALA is a small-cap quality compounder stock; OCUL is a small-cap quality compounder stock; VUZI is a small-cap high-growth stock. VUZI pays a dividend while GAUZ, KALA, OCUL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.